
    
      Stage IV colorectal cancer(CRC) has poor survival rate in spite of the development of
      chemotherapeutic agents. It is regarded as a standard palliative chemotherapy using with both
      targeted agents and cytototic chemotherpeutic agents. However, it is still demanding to treat
      stage IV CRC patients, who are refractory responses in these chemotherapeutics. In addition,
      patients were suffered from the various adverse events by the repetive cytotoxic
      chemotherapies.
    
  